Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027

Q32 Bio Inc.

2025-Q2 EPS reported -$1.68

Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.
Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.
SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.
Fast Track designation granted by FDA for bempikibart in alopecia areata.
Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.